Responses to selinexor in multiple myeloma

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma

Increased levels of the nuclear export protein, exportin 1 (XPO1), were demonstrated in multiple myeloma (MM) patients. Targeting XPO1 with selinexor (the selective inhibitor of nuclear export; SINE compound KPT-330) demonstrates broad antitumor activity also in patient cells resistant to bortezomib; hence, it is a promising target in MM patients. Hypoxia is known to mediate tumor progression a...

Multiple Myeloma Update

This literature review presents the most recent developments in the management of multiple myeloma, which is characterized by the presence of abnormal plasma cells (myeloma cells) that accumulate into the bone marrow. Aspects related to pathophysiology, clinical manifestations, laboratory, study and treatment are described. These pieces of information  are necessary to accomplish a better ...

Treatment of Multiple Myeloma

Les traitements classiques de myelome multiple et les schemas differents proposes ont ete mis en revue.  La poly chimiotherapie de la maladie avec une com-binaison de cyclophosphamide, B.C.N.U. Alkeran, Perdnisone et Vincristine a donnee une meilleur Resultat ceci surtout dans les formes graves et rapidement progressive de la maladie. D'autres sehemas therapeutiques sont en cours. 

Enhancing Therapeutic Radiation Responses in Multiple Myeloma

hematuria in multiple myeloma

. frequent macroscopic hematuria in multiple myeloma is quite rare and exceptional and no report has been found in the literature. we have presented a case of multiple myeloma who developed frequent episodes of gross hematuria during her long lasting but slowly progressing course of the disease